XML 36 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Collaborations, contracts and licensing agreements (Tables)
 6 Months Ended
Jun. 30, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of deferred collaborations and contracts revenue The following table outlines the transaction price and the changes to the related asset and liability balances during the six months ended June 30, 2023:
Six Months Ended June 30, 2023
Transaction PriceCumulative Collaboration Revenue RecognizedDeferred License Revenue
(in thousands)
Combined performance obligation$49,270 $33,143 $16,127 
Less contract asset(800)
Total deferred license revenue15,327 
Less current portion of deferred license revenue15,327 
Non-current deferred license revenue$— 
Summary of collaborations Revenues are summarized in the following table:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
(in thousands)(in thousands)
Revenue from collaborations and licenses
Acuitas Therapeutics, Inc.$861 $1,550 $2,266 $3,084 
Qilu Pharmaceutical Co., Ltd.3,024 11,024 7,128 20,655 
Other milestone and royalty payments— (18)— 35 
Non-cash royalty revenue
Alnylam Pharmaceuticals, Inc.766 1,685 1,944 3,048 
Total revenue$4,651 $14,241 $11,338 $26,822